Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1A1 | P14550 | 17/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 17/20 | 1.00 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imirestat SCHEMBL30924520 | 1.00 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9810984 | 0.94 | AKR1A1 (0.88) | AKR1A1AKR1B1ITGA4 | |
| Alconil SCHEMBL30661866 | 0.92 | AKR1A1 (0.85) | AKR1A1AKR1B1ITGA4 | |
| Alconil SCHEMBL1201487 | 0.92 | AKR1A1 (0.85) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL10928977 | 0.91 | AKR1A1 (0.82) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL9673837 | 0.91 | AKR1A1 (0.82) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL20845832 | 0.91 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL10927385 | 0.91 | AKR1A1 (0.82) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL21095648 | 0.87 | AKR1A1 (0.76) | AKR1A1AKR1B1ITGA4 | |
| SCHEMBL20845824 | 0.87 | AKR1A1 (0.76) | AKR1A1AKR1B1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1034 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719592-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4695239-A1 | DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| US-12551467-B2 | Compositions and methods of modulating S-nitrosylation | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-02-17 | — | — | US | claimed |
| EP-3226859-B1 | AKR1A1 INHIBITORS FOR USE IN LOWERING CHOLESTEROL AND MODULATE S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119113121-A | Pharmaceutical composition and preparation and application thereof | 清华大学 | 2024-12-13 | — | — | CN | claimed |
| WO-2024249612-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240374693-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2024-11-14 | — | — | US | claimed |
| US-20240366568-A1 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | UNIV CASE WESTERN RESERVE (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024216034-A1 | DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| US-12083168-B2 | Treatment and detection of inherited neuropathies and associated disorders | UNIVERSITY OF MIAMI (US) | 2024-09-10 | — | — | US | claimed |
| US-6232330-B1 | THERAPEUTICALLY EFFECTIVE AMOUNT OF AN INSULIN SENSITIVITY ENHANCER(PIOGLITAZONE,TROGLITAZONE AND SALTS) IN COMBINATION WITH AN ALDOSE REDUCTASE INHIBITOR(TOLURESTAT,EPALRESTAT,IMIRESTAT,ZENARESTAT) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-15 | — | — | US | claimed |
| US-6218409-B1 | ADMINISTERING INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH AN ALDOSE REDUCTASE INHIBITOR FOR REDUCING SIDE EFFECTS OF DIABETIC DRUGS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | claimed |
| US-6156773-A | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | claimed |
| WO-2000045818-A1 | USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | claimed |
| CN-1261804-A | Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor | ZENECA LTD (GB) | 2000-08-02 | — | — | CN | claimed |
| WO-2000037066-A2 | A METHOD FOR THE PROPHYLACTIC TREATMENT OF CATARACTS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-06-29 | — | — | WO | claimed |
| EP-0991424-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALDOSE REDUCTASE INHIBITOR AND AN ACE INHIBITOR | ZENECA LIMITED (GB) | 2000-04-12 | — | — | EP | claimed |
| WO-1999002189-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALDOSE REDUCTASE INHIBITOR AND AN ACE INHIBITOR | ZENECA LIMITED (GB) | 1999-01-21 | — | — | WO | claimed |
| EP-0258476-B1 | ALDOSE REDUCTASE INHIBITORS USEFUL IN GLAUCOMA THERAPY | ALCON LABORATORIES, INC. (US) | 1990-04-25 | — | — | EP | claimed |
| US-4609663-A | Aldose reductase inhibitors useful in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1986-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551467-B2 | Compositions and methods of modulating S-nitrosylation | AKR1A1, AKR1B1, AKR1D1 | AKR1A1 1/4885AKR1B1 2/4885ITGA4 2959/4885 |
| US-20240366568-A1 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | PDK4, AK1, PDK1 | AKR1A1 9/4885AKR1B1 11/4885ITGA4 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.